. Author manuscript; available in PMC: 2021 Feb 4.

Published in final edited form as: Pediatr Blood Cancer. 2016 Oct 20;64(3):10.1002/pbc.26273. doi: 10.1002/pbc.26273

TABLE 4.

Fold increase from pre-treatment to the time of engraftment for patients with and without ES. Medians and upper and lower quartiles are reported

	Engraftment syndrome
	Present	Absent	P
N	5	25
IFN-γ	1.00 (1.00, 2.97)^a	1.81 (1.14, 7.67)	0.54
IL-1b	1.00 (1.00, 1.50)	1.00 (1.00, 1.00)	0.39
IL-6	2.79 (1.00, 5.63)	1.10 (0.35, 3.68)	0.36
IL-8	2.97 (1.18, 4.99)	0.85 (0.45, 1.89)	0.23
IL-10	4.21 (2.05, 4.60)	1.57 (0.87, 3.25)	0.17
IL-12p70	1.00 (0.44, 2.57)	1.00 (0.37, 1.00)	0.58
TNF-α	0.74 (0.60, 2.63)	0.83 (0.45, 1.20)	0.67
PCT	15.1 (14.2, 66.0)	2.31 (0.64, 2.47)	0.0006

ES, engraftment syndrome; IFN, interferon; IL, interleukin; PCT, procalcitonin; TNF, tumor necrosis factor.

Median (lower and upper quartile), all values represent the fold increase from pre-treatment (prior to the start of conditioning) to the time of engraftment.

Wilcoxon rank sum test was used to compare ES groups.